Filtered By:
Condition: Heart Failure
Education: Study
Management: Hospitals
This page shows you your search results in order of relevance. This is page number 7.
Order by Relevance | Date
Total 321 results found since Jan 2013.
Racial Differences in Incidence and Clinical Course of Atrial Fibrillation and What Remains to be Investigated
Abstract
There are many risk factors identified for atrial fibrillation (AF), some of which differ between blacks and whites. These differences and differences in stroke occurrence and clinical course of AF between blacks and whites are reviewed. Risk factors identified to date include age, white race, male sex, body mass index (BMI) ≥30, height ≥173 cm, weight, increased waist circumference, higher levels of systolic (SBP) and diastolic blood pressure (DBP), increased pulse pressure, diagnosis of hypertension, antihypertensive medication use, HDL <40 mg/dL, triglycerides >200 mg/dL, lower heart rate...
Source: Current Cardiovascular Risk Reports - January 27, 2015 Category: Cardiology Source Type: research
Early and late clinical outcomes of endovascular, surgical, and hybrid revascularization strategies of combined carotid and coronary artery diseases: the FRIENDS study group (Finalized Research In ENDovascular Strategies)
The best therapeutic strategy for patients with concomitant carotid obstructive disease (COD) and coronary artery disease (CAD) remains controversial. The aim of the study is to observe post-procedural and 1-year clinical outcomes of patients with COD and CAD after an endovascular, surgical, or a combined (hybrid) revascularization approach, selected by consensus of a multidisciplinary team. Between January 2006 and December 2012, 1043 consecutive patients with COD and concomitant CAD were treated. According to treatment strategies, patients were divided into three groups: surgical: 391 patients (37.1%), endovascular: 502 ...
Source: European Journal of Heart Failure Supplements - March 10, 2015 Category: Cardiology Authors: Castriota, F., Tomai, F., Gabrio Secco, G., Reimers, B., Piccoli, A., De Persio, G., Pesarini, G., Schiavina, G., Borioni, R., Pacchioni, A., Cremonesi, A., Vassanelli, C., Ribichini, F. Tags: Articles Source Type: research
Antiplatelet therapy in Takotsubo cardiomyopathy: does it improve cardiovascular outcomes during index event?
Abstract
Plasma catecholamines may play an important role in Takotsubo cardiomyopathy (TCM) pathophysiology. Patients with disproportionately high catecholamine responses to stressful events are prone to worse clinical outcomes. Catecholamines stimulate platelet activation and, therefore, may determine the clinical presentation and outcomes of TCM. We conducted a retrospective, descriptive study TCM patients admitted between 2003 and 2013 to Einstein Medical Center, Philadelphia, PA, USA and Danbury Hospital, Danbury, CT, USA. A total of 206 patients met Modified Mayo TCM criteria. Using a multiple logistic model,...
Source: Heart and Vessels - August 13, 2015 Category: Cardiology Source Type: research
New Quality Measure Seeks to Optimize Cardiovascular Care For African Americans
In recent months, the debate on race and policing in this country has ignited passions and raised important questions. But while headlines have highlighted instances of excessive force by police and the discriminatory treatment of African Americans, the conversation hasn't yet made the logical leap to a discussion around unequal access to care. It is widely accepted in medical literature that African Americans, Hispanics, and the poor are receiving substandard health care. By way of example, the treatment of heart disease should not be a matter of race; it should be a matter of science and medicine. Today, there are thous...
Source: Healthy Living - The Huffington Post - September 2, 2015 Category: Consumer Health News Source Type: news
Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial
Publication date: Available online 22 October 2015 Source:The Lancet Author(s): Sanjit S Jolly, John A Cairns, Salim Yusuf, Michael J Rokoss, Peggy Gao, Brandi Meeks, Sasko Kedev, Goran Stankovic, Raul Moreno, Anthony Gershlick, Saqib Chowdhary, Shahar Lavi, Kari Niemela, Ivo Bernat, Warren J Cantor, Asim N Cheema, Philippe Gabriel Steg, Robert C Welsh, Tej Sheth, Olivier F Bertrand, Alvaro Avezum, Ravinay Bhindi, Madhu K Natarajan, David Horak, Raymond C M Leung, Saleem Kassam, Sunil V Rao, Magdi El-Omar, Shamir R Mehta, James L Velianou, Samir Pancholy, Vladimír Džavík Background Two ...
Source: The Lancet - October 23, 2015 Category: Journals (General) Source Type: research
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
Publication date: Available online 18 March 2016 Source:The Lancet Diabetes & Endocrinology Author(s): Jason H Y Wu, Celine Foote, Juuso Blomster, Tadashi Toyama, Vlado Perkovic, Johan Sundström, Bruce Neal Background In patients with type 2 diabetes, sodium-glucose cotransporter-2 (SGLT2) inhibitors are known to reduce glucose concentrations, blood pressure, and weight, but to increase LDL cholesterol and the incidence of urogenital infections. Protection against cardiovascular events has also been reported, as have possible increased risks of adverse outcomes such as ketoacidosis and bone fracture. We a...
Source: The Lancet Diabetes and Endocrinology - March 19, 2016 Category: Endocrinology Source Type: research
Better than Aspirin for Your Heart
If you’ve been diagnosed with heart disease, the chances are you’ve been told to take low-dose aspirin every day as a preventative measure against heart attack and stroke.
It’s most commonly prescribed for patients with congestive heart failure. This is the inability of your heart to pump as much blood as your body needs.
And this is a big worry to me, because there is very little evidence that aspirin helps. In fact, regular use of aspirin — even baby aspirin — can do you more harm than good.
Common Aspirin Beliefs
The idea is that aspirin thins the blood, making it easier to pump. It is also s...
Source: Al Sears, MD Natural Remedies - April 1, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Heart Health Source Type: news
HRS 2016 roundup: Leadless pacers at the fore
Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ), aiming to distinguish their respective leadless pacemaker offerings, presented new data last week in San Francisco at the Heart Rhythm Society’s annual meeting.
St. Jude said a subset of data from the Leadless II trial showed that its Nanostim device was was successfully retrieved in 14 patients up to 3.2 years after implantation, with no serious adverse events.
“We’ve now shown that for patients requiring device upgrades or new leadless pacing options, late retrievability – even up to 3 years – is possible with the Nanostim leadless pacemak...
Source: Mass Device - May 9, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Boston Scientific Cardiac Rhythm Management HRS 2016 Medtronic St. Jude Medical Source Type: news
Effectiveness of the influenza vaccine in preventing admission to hospital and death in people with type 2 diabetes.
Authors: Vamos EP, Pape UJ, Curcin V, Harris MJ, Valabhji J, Majeed A, Millett C
Abstract
BACKGROUND: The health burden caused by seasonal influenza is substantial. We sought to examine the effectiveness of influenza vaccination against admission to hospital for acute cardiovascular and respiratory conditions and all-cause death in people with type 2 diabetes.
METHODS: We conducted a retrospective cohort study using primary and secondary care data from the Clinical Practice Research Datalink in England, over a 7-year period between 2003/04 and 2009/10. We enrolled 124 503 adults with type 2 diabetes. Outcome me...
Source: Canadian Medical Association Journal - July 28, 2016 Category: Journals (General) Tags: CMAJ Source Type: research
ACC ’ 18 Roundup: Abbott releases long-term HeartMate 3 data
Abbott (NYSE:ABT) touted two-year data yesterday from its trial designed to compare the company’s HeartMate 3 left ventricular assist device to its HeartMate 2 device in patients with advanced heart failure.
Data from the study were published in The New England Journal of Medicine and presented at the American College of Cardiology’s 67th Annual Scientific Session.
More than 1,000 patients participated in the study. Researchers assessed the trial’s participants for a short-term endpoint of six months and long-term endpoint of two years.
The two-year cohort met its primary endpoint, achieving 77.9% event...
Source: Mass Device - March 12, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Clinical Trials Diagnostics Food & Drug Administration (FDA) Regulatory/Compliance Research & Development Wall Street Beat Abbott Aetna AliveCor iRhythm Technologies Inc. Jan Source Type: news
Abstract 175: Atrial Fibrillation in the USF Resident Clinics: Quality-Driven Medical Therapy Session Title: Poster Session AM
Patients with atrial fibrillation (afib) have a high rate of serious complications including stroke and decompensated heart failure. While patients with afib are five times more likely to suffer a stroke in their lifetime than the general population, this risk can be reduced by 64% with appropriate anticoagulation using warfarin or approved novel oral anticoagulants (NOACs). Reducing the morbidity and mortality from excess strokes is a common interest nationwide due to unsustainable healthcare costs, increasing human resource gaps in medicine, and payment reforms that hold physicians and healthcare organizations financiall...
Source: Circulation: Cardiovascular Quality and Outcomes - April 5, 2018 Category: Cardiology Authors: Sadic, E. Tags: Session Title: Poster Session AM Source Type: research
Assessment of functional capacity before major non-cardiac surgery: an international, prospective cohort study
Publication date: 30 June–6 July 2018 Source:The Lancet, Volume 391, Issue 10140 Author(s): Duminda N Wijeysundera, Rupert M Pearse, Mark A Shulman, Tom E F Abbott, Elizabeth Torres, Althea Ambosta, Bernard L Croal, John T Granton, Kevin E Thorpe, Michael P W Grocott, Catherine Farrington, Paul S Myles, Brian H Cuthbertson Background Functional capacity is an important component of risk assessment for major surgery. Doctors' clinical subjective assessment of patients' functional capacity has uncertain accuracy. We did a study to compare preoperative subjective assessment with alternative markers of fitness (cardiopulmon...
Source: The Lancet - June 29, 2018 Category: General Medicine Source Type: research
Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition
AbstractPurpose of ReviewTo distinguish extreme and very high atherosclerotic cardiovascular disease (ASCVD) event risk based on prospective epidemiological studies and clinical trial results.Recent FindingsClinical practice guidelines have categorized patients with either a history of one or more “clinical ASCVD” events or “coronary heart disease (CHD) risk equivalency” to be at “very high risk” for a recurrence or a first event, respectively. A 20% or greater 10-year ASCVD risk for a composite 3-point “major” atherosclerotic cardiovascular event (MACE) of non-fatal myocardia l infarction (MI), non-fatal s...
Source: Current Diabetes Reports - July 21, 2019 Category: Endocrinology Source Type: research
